Form 4: Avalo Therapeutics Director Trades Under 10b5-1 Plan
Statement of Changes in Beneficial Ownership
Avalo Therapeutics Director Mitchell Chan executed a series of stock transactions under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Director Mitchell Chan reported transactions involving Avalo Therapeutics, Inc. common stock.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on November 19, 2025.
- The earliest transaction date reported is May 6, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions under a pre-established plan, providing no new material financial or strategic information.
Future Outlook
No specific future outlook or guidance is provided in this filing.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive and director trading activities. The use of a Rule 10b5-1 plan indicates a structured approach to stock sales, often employed to avoid accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| 11/19/2025 | Date Rule 10b5-1 trading plan was adopted by Reporting Person. |
| 05/06/2026 | Earliest transaction date reported. |
| 05/07/2026 | Date of signature for the Form 4 filing. |
Keywords
Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Avalo Therapeutics, Director Transactions, Stock Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.